Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance

Amphastar Pharmaceuticals IncTrade
Consumer Discretionary Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHXLY
Market Cap
$863.95M
Sector
Health
52-Week High
$30.81$124.52
52-Week Low
$16.87$105.64
Enterprise Value
$1.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Consumer Discretionary Select Sector SPDR Fund

XLY trades at $119.86, up 1.47% with strong bullish technical momentum indicated by moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The consumer discretionary ETF shows resilience amid economic uncertainty, with recent news highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions on short-term RSI but strong trend momentum on ADX readings.

XLY presents a bullish case with strong technical momentum and unanimous analyst support, though current RSI levels suggest potential near-term consolidation. The ETF's performance hinges on consumer discretionary spending trends amid evolving inflation dynamics. Key risks include consumer confidence erosion and broader economic pressures affecting discretionary purchases.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Consumer Discretionary Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.

Read more on XLY